Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 6 of the 28 sources its claims cite were checked for support.
Abstract
Succinylacetone (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumarylacetoacetate hydrolase. It is known that patients with this hereditary disease excrete excessive amounts of delta-aminolevulinic acid (ALA) in urine and that certain patients have an accompanying clinical syndrome resembling that of acute intermittent porphyria (AIP). In order to elucidate the relation of succinylacetone to the heme biosynthetic pathway, we have examined the effects of this metabolite on the cellular heme content of cultured avian hepatocytes and on the activity of purified ALA dehydratase from normal human erythrocytes and from mouse and bovine liver. Our data indicate that succinylacetone is an extremely potent competitive inhibitor of ALA dehydratase in human as well as in animal tissues. By using purified preparations of the enzyme from human erythrocytes and mouse and bovine liver, an inhibitor constant ranging from 2 x 10(-7) M to 3 x 10(-7) M was obtained. In cultured hepatocytes, succinylacetone also inhibited ALA dehydratase activity, decreased the cellular content of heme and cytochrome P-450, and greatly potentiated the induction response of ALA synthase to drugs such as phenobarbital, chemicals such as allylisopropylacetamide and 3,5-dicarbethoxy-1,4-dihydrocollidine, and natural steroids such as etiocholanolone. Four patients with hereditary tyrosinemia have been studied and all were found to have greatly depressed levels of erythrocyte ALA dehydratase activity and elevated concentrations of this inhibitor in urine. These findings indicate that tyrosinemia is a disorder of special pharmacogenetic interest because succinylacetone, an abnormal product of the tyrosine metabolic pathway, resulting from the primary gene defect of the disease, profoundly inhibits heme biosynthesis in normal cells through a blockade at the ALA dehydratase level, leading to clinical and metabolic consequences that mimic another genetic disease, AIP.
Overview
CoChat Summary
TL;DR
This paper shows that succinylacetone, a metabolite that accumulates in hereditary tyrosinemia, is a very potent competitive inhibitor of δ-aminolevulinic acid dehydratase (ALA dehydratase), linking the disorder to blocked heme biosynthesis. In cultured chick embryo liver cells it lowers heme and cytochrome P-450 and greatly sensitizes ALA synthase induction, helping explain AIP-like features in some patients.
Key findings
- Succinylacetone competitively inhibited purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, with inhibitor constants in the range of 2–3 × 10^-7 M and enzyme Km values of 1.5–2.2 × 10^-4 M, implying about 1,000-fold greater affinity for the enzyme than ALA.
- In cultured chick embryo liver cells, succinylacetone caused dose-dependent inhibition of ALA dehydratase and reduced heme metabolism; at 10^-8 M it decreased cytochrome P-450 by >50%, and total heme fell from 155±8 to 112±3 pmol/mg protein.
- Succinylacetone potentiated ALA synthase induction by porphyrogenic agents by about 3- to 16-fold; with AIA, the lowest detectable induction shifted from >0.5 μg/ml to 0.05 μg/ml (a 10-fold increase in sensitivity).
- In the four hereditary tyrosinemia patients studied, erythrocyte ALA dehydratase activity ranged from 0.4% to 38% of control; in one case it was below the detection limit (<10 nmol PBG/ml RBC·h), and the patient’s urine inhibited normal ALA dehydratase by 28–79%.
Methods
- The study examined four patients with hereditary tyrosinemia, purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, and used cultured chick embryo liver cells to test heme metabolism and induction responses.
- ALA dehydratase was purified by chromatography and fractionation methods; inhibition was assayed using purified enzyme preparations and liver-cell homogenates, and heme, cytochrome P-450, heme oxygenase, and ALA synthase were measured in cultured hepatocytes.
- Main analyses included competitive inhibition kinetics (including Dixon plots and Km/Ki comparisons), dose-response assays in cell culture, and rocket immunoelectrophoresis to assess whether patient erythrocytes contained normal amounts of ALA dehydratase protein.
Limitations
- The paper explicitly notes that some findings are “unpublished results” and that one patient’s post-treatment enzyme values were reported as “submitted for publication”, so not all supporting data are fully presented here.
- The text gives only a small clinical sample: four patients with hereditary tyrosinemia, which limits generalization; this is evident from the study design.
- The paper states that several mechanistic points remain speculative, including how succinylacetone blocks ALA binding and the precise basis of the AIP-like neurological symptoms; this is stated in the discussion as unresolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
6 Valid · 1 Not valid · 12 Not checked · 58 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Succinylacetone (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumarylacetoacetate hydrolase.”
What the sources say
- Partly supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. sourceExperimental — accuracy not yet measured
The Abstract (p. 4641) reports succinylacetone in urine from patients with hereditary tyrosinemia and identifies a possible block at the fumarylacetoacetase step. It says the metabolites “presumably” originate from upstream compounds and suggests that decreased enzyme activity “may be” the primary defect; it does not establish the inherited deficiency as the cause asserted in the claim. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with this disease excrete excessive amounts of urinary δ-aminolevulinic acid (ALA)¹ (25) and have low ALA dehydratase [EC 4.2.1.24] activity in erythrocytes (6, 7) and in liver (7).”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Strife, C..F., E. L. Zuroweste, and E. A. Emmett. 1977. Tyrosinemia with acute intermittent porphyria: aminolevulinic acid dehydratase deficiency related to elevated urinary aminolevulinic acid levels. J. Pediatr. 90: 400-404. source
- Supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. source
The Abstract in our indexed copy reports that porphobilinogen synthase (EC 4.2.1.24), the enzyme identified in the citing sentence as ALA dehydratase, had markedly reduced activity in both erythrocytes and liver tissue from patients with hereditary tyrosinemia. No page number is supplied for the passage. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has also been established that the levels of this enzyme activity in clinically manifest AIP patients and in clinically latent gene carriers are equally diminished (~50%) from normal (35), indicating that the PBG deaminase defect alone does not determine the induction of hepatic ALA synthase that occurs in clinically manifest AIP (35).”
What the sources say
- Supportedcites [35] 35. Sassa, S., S. Granick, D. R. Bickers, H. L. Bradlow, and A. Kappas. 1974. A microassay for uroporphyrinogen I synthase, one of three abnormal enzyme activities in acute intermittent porphyria, and its application to the study of the genetics of this disease. Proc. Natl. Acad. Sci. USA. 71: 732–736. source
The CONCLUDING COMMENTS of our copy state the point directly: 'It seems unlikely, therefore, that the low URO synthase activity in the liver cells of AIP patients can alone depress hepatic heme synthesis sufficiently to lead to secondary stimulation of ALA synthase production. To elicit the overproduction of this enzyme in individuals carrying the low URO synthase trait, other metabolic factors appear to be required' — URO synthase (EC 4.3.1.8) being the enzyme the field also calls PBG deaminase, as the Abstract and RESULTS AND DISCUSSION make clear. The same section adds that the URO synthase defect 'is clearly not of itself sufficient to determine clinical expression of the AIP trait' and that latent carriers show the same roughly one-half-normal erythrocyte levels as manifest patients (Table 1, Fig. 2), matching the preceding clause of the citing sentence. The source phrases its conclusion with mild hedging ('seems unlikely', 'appear to be required'), but its substantive content is the claim's. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low ALA dehydratase activity is thought to result from enzyme inhibition by accumulation of succinylacetone (4,6-dioxoheptanoic acid) in plasma resulting from the deficiency of 4-fumarylacetoacetate hydrolase [EC 3.7.1.2] in this disease (7).”
What the sources say
- Partly supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. sourceExperimental — accuracy not yet measured
The passage labeled Abstract reports very low porphobilinogen synthase (ALA dehydratase) activity in hereditary tyrosinemia, identifies succinylacetone as an inhibitor in patients’ urine, and suggests a block at the fumarylacetoacetase step. It does not establish the claim’s specific location of succinylacetone accumulation in plasma. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The activity of the enzyme ranged from 0.4 to 38% of control incubations with normal erythrocytes (RBC).”
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 77 claims and to verify the 2 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SA accumulation is thus the indirect result of the complete or incomplete block of the FAH enzyme, and SA accumulation has been linked to certain pathological aspects of the disorder (1, 2, 37, 38).”
From Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 (2001) · cites this paper as [37]
Experimental — accuracy not yet measured
Citations
Cites
Weber, K., & Osborn, M. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94333-4 · Cited by 20,298
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
Laurell, C.-B. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90246-6 · Cited by 4,401
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“(7) first reported that the high urinary excretion of ALA in patients with hereditary tyrosinemia is due to inhibition of ALA dehydratase by succinylacetone and their studies indicated that the primary enzymatic defect in hereditary tyrosinemia might be a decreased activity of fumarylacetoacetate hydrolase, an enzyme…”
Backgroundδ-Aminolevulinic Acid Synthetase
Marver, H. S., Collins, A., Tschudy, D. P., & Rechcigl, M. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99725-5 · Cited by 290
Maines, M., & Kappas, A. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41402-6 · Cited by 224
Self-citationδ-Aminolevulinic Acid Dehydratase of Rhodopseudomonas spheroides
Nandi, D. L., & Shemin, D. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)56978-2 · Cited by 213
Immunochemical Studies on Electron Transport Chains Involving Cytochrome P-450
Masters, B. S. S., Baron, J., Taylor, W. E., Isaacson, E. L., & LoSpalluto, J. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62065-4 · Cited by 211
Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes.
Anderson, P. M., & Desnick, R. J. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50263-5 · Cited by 175
Granick, J. L., Sassa, S., Granick, S., Levere, R. D., & Kappas, A. (1973) · Biochemical Medicine · doi:10.1016/0006-2944(73)90018-5 · Cited by 173 · cited 1×
“24 h display no toxicity from this compound because the activity of ALA dehydratase is dependent on the integrity of the cells that is essential for the regeneration of reduced glutathione, an essential cofactor for this enzyme; the loss of this capacity would be a sensitive index of cellular damage (21).”
BackgroundSelf-citationSassa, S., & Kappas, A. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40571-0 · Cited by 159
Self-citation
Research works printed but not linked: 2
- [1]1. LaDu, B. N., and L. R. Gjessing. 1978. Tyrosinosis and tyrosinemia. In The Metabolic Basis of Inherited Disease. J. B. Stanbury, J. B. Wyngaarden, and D. S. Frederickson, editors. McGraw-Hill, New York. 4th edition. 256-267.
- [38]38. Kappas, A., S. Sassa, and K. E. Anderson. 1982. The porphyrias. In The Metabolic Basis of Inherited Disease. j. B. Śtanbury, J. B. Wyngaarden, D. S. Frederickson, J. S. Goldstein, and M. S. Brown, editors. McGraw-Hill, New York, 5th edition. 1301-1384.
Cited by
Puy, H., Gouya, L., & Deybach, J.-C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61925-5 · Cited by 729
Rev-erbα, a Heme Sensor That Coordinates Metabolic and Circadian Pathways
Yin, L., Wu, N., Curtin, J. C., Qatanani, M., Szwergold, N. R., Reid, R. A., Waitt, G. M., Parks, D. J., Pearce, K. H., Wisely, G. B., et al. (2007) · Science · doi:10.1126/science.1150179 · Cited by 707
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493
Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 232
Heme biosynthesis and the porphyrias
Phillips, J. D. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.04.008 · Cited by 215
Modern diagnosis and management of the porphyrias
Sassa, S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06289.x · Cited by 191
“The most potent inhibitor of ALAD is succinylacetone (Sassa & Kappas, 1983), a structural analogue of ALA, which is found in the urine and blood of patients with hereditary tyrosinemia type 1 (Lindblad et al, 1977).”
BackgroundSelf-citationScott, C. R. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30092 · Cited by 186
“Succinylacetone is a potent inhibitor of two enzymes: 4-hydroxyphenylpyruvic acid dioxygenase (4-HPPD) and d-ALA dehydratase [Sassa and Kappas, 1983].”
BackgroundHypermethioninemias of genetic and non‐genetic origin: A review
Mudd, S. H. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30293 · Cited by 181
“Succinylacetone may play a prominent role in episodes of porphyria-like peripheral neuropathy due to its profound inhibition of delta-aminolevulinic acid dehydratase, thereby blocking heme biosynthesis [Sassa and Kappas, 1983].”
BackgroundLead Binding to δ‐Aminolevulinic Acid Dehydratase (ALAD) in Human Erythrocytes
Bergdahl, I. A., Grubb, A., Schütz, A., Desnick, R. J., Wetmur, J. G., Sassa, S., & Skerfving, S. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb02061.x · Cited by 178
Self-citationPorphyria Diagnostics—Part 1: A Brief Overview of the Porphyrias
Ramanujam, V. S., & Anderson, K. E. (2015) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1720s86 · Cited by 158
Role of Delta-aminolevulinic Acid in the Symptoms of Acute Porphyria
Bissell, D. M., Lai, J. C., Meister, R. K., & Blanc, P. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.026 · Cited by 94
Vergères, G., Yen, T. S. B., Aggeler, J., Lausier, J., & Waskell, L. A. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.1.249 · Cited by 91
Fujita, H., Yamamoto, M. P., Yamagami, T., Hayashi, N., & Sassa, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47399-7 · Cited by 81
Self-citationIngi, T., Chiang, G., & Ronnett, G. V. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-18-05621.1996 · Cited by 78
“…significantly inhibited ALA dehydratase activity in olfactory receptor neurons, which resulted in the accumulation of ALA. SA is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumaryl acetate hydrolase (Sassa and Kappas, 1983).”
BackgroundKubo, S., Sun, M., Miyahara, M., Umeyama, K., Urakami, K.-I., Yamamoto, T., Jakobs, C., Matsuda, I., & Endo, F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9552 · Cited by 78
Hamilton, J. W., Bement, W. J., Sinclair, P. R., Sinclair, J. F., & Wetterhahn, K. E. (1989) · Biochemical Journal · doi:10.1042/bj2570936 · Cited by 77
Iron metabolism in K562 erythroleukemic cells.
Bottomley, S. S., Wolfe, L., & Bridges, K. R. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88852-4 · Cited by 73
Vaisman, B., Fibach, E., & Konijn, A. M. (1997) · Blood · doi:10.1182/blood.v90.2.831 · Cited by 72
Lim, C. E. L., Matthaei, K. I., Blackburn, A. C., Davis, R. P., Dahlstrom, J. E., Koina, M. E., Anders, M. W., & Philip G. Board (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63332-9 · Cited by 74
“Although the determination of SA concentrations by the inhibition of -ALAD is a well-established technique, it is an indirect measurement.(16,34,59) Recent studies of a rat model of GSTZ1-1 deficiency show that other metabolites such as MA or FA also inhibit -ALAD.”
BackgroundMethodExperience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1
Santra, S., & Baumann, U. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1229 · Cited by 68
“SA has been shown to directly inhibit glucose and amino acid transport in the renal tubule [12] and it is a potent inhibitor of the δ -aminolevulinic acid dehydratase step in porphyrin synthesis, causing the porphyria-like neurological crises described in patients with HT1 [13,14] .”
BackgroundAponte, J. L., Sega, G. A., Hauser, L. J., Dhar, M. S., Withrow, C. M., Carpenter, D. A., Rinchik, E. M., Culiat, C. T., & Johnson, D. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.641 · Cited by 68
Beri, R., & Chandra, R. (1993) · Drug Metabolism Reviews · doi:10.3109/03602539308993973 · Cited by 68
Fibach, E., Kollia, P., Schechter, A. N., Noguchi, C., & Rodgers, G. (1995) · Blood · doi:10.1182/blood.v85.10.2967.bloodjournal85102967 · Cited by 72
Best practice guidelines on first-line laboratory testing for porphyria
Woolf, J., Marsden, J. T., Degg, T. J., Whatley, S. D., Reed, P., Brazil, N., Stewart, M. F., & Badminton, M. N. (2016) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563216667965 · Cited by 66
Lead Effects on the Heme Biosynthetic Pathway Relationship to Toxicity
Moore, M. R., Goldberg, A., & Laiwah, A. C. Y. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb48774.x · Cited by 61
Ishida, N., Fujita, H., Fukuda, Y., Noguchi, T., Manfred Otto, D. O. S. S., Kappas, A., & Sassa, S. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115732 · Cited by 58
“, lead (5), succinylacetone (6, 7), as well as by an inherited ALADdeficiency (8, 9), which may result in the development of a clinically severe hepatic porphyria (3, 4).”
BackgroundSelf-citationThe Dichloroacetate Dilemma: Environmental Hazard versus Therapeutic Goldmine—Both or Neither?
Stacpoole, P. W. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002554 · Cited by 59
“Succinylacetone is a competitive inhibitor of δ-aminolevulinate dehydratase (enzyme– inhibitor dissociation constant Ki = 0.3 µM; Sassa and Kappas 1983), which catalyzes an early step in heme biosynthesis.”
BackgroundInfluentialThe mitochondrial carrier SFXN1 is critical for complex III integrity and cellular metabolism
Acoba, M. G., Alpergin, E. S. S., Renuse, S., Fernández-del-Río, L., Lu, Y., Khalimonchuk, O., Clarke, C. F., Pandey, A., Wolfgang, M. J., & Claypool, S. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108869 · Cited by 64
“…heme deficiency affects protein abundance of ETC complex subunits independent of a perturbed serine metabolism, we treated cells with increasing concentrations of succinylacetone (SA), which blocks heme biosynthesis by inhibiting ALAD (Figure 6A) (Sassa and Kappas, 1983; Tschudy et al., 1981).”
BackgroundMethodTuchman, M., Freese, D. K., Sharp, H. L., Ramnaraine, M. L. R., Ascher, N. L., & Bioomer, J. R. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80501-2 · Cited by 54
Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis
Fukuda, Y., Wang, Y., Lian, S., Lynch, J., Nagai, S., Fanshawe, B., Kandilci, A., Janke, L. J., Neale, G., Fan, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92409 · Cited by 52
Garcia, G. A., Cohen, S. I. A., Dobson, C. M., & Knowles, T. P. J. (2014) · Physical Review E · doi:10.1103/physreve.89.032712 · Cited by 49
Akagi, R., Kato, N., Inoue, R., Anderson, K. E., Jaffe, E. K., & Sassa, S. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.10.011 · Cited by 50
Self-citationBustad, H. J., Kallio, J. P., Vorland, M., Fiorentino, V., Sandberg, S., Schmitt, C., Aarsand, A. K., & Martínez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020675 · Cited by 50
“Patients with hereditary tyrosinemia may also present with increased ALA excretion and experience neurologic crises comparable with those seen in AIP [61].”
BackgroundAdhikari, A., Penatti, C. A. A., Resende, R. R., Ulrich, H., Britto, L. R. G., & Bechara, E. J. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.103 · Cited by 47
“…that the neuropsychiatric manifestations of these diseases, which include mood disorders, aggressiveness, hallucinations, convulsions and seizures (Sassa and Kappas, 1983), are associated with . accumulation of ALA (Kappas et al., 1995) due to enzymatic deficiencies in the heme biosynthetic…”
BackgroundSynthesis, delivery and regulation of eukaryotic heme and Fe–S cluster cofactors
Barupala, D., Dzul, S. P., Riggs-Gelasco, P. J., & Stemmler, T. L. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.01.010 · Cited by 59
Purification and properties of 5-aminolaevulinate dehydratase from human erythrocytes
Gibbs, P. N. B., Chaudhry, A. G., & Jordan, P. M. (1985) · Biochemical Journal · doi:10.1042/bj2300025 · Cited by 44
Current Strategies for the Treatment of Hereditary Tyrosinemia Type I
Ashorn, M. H., Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608010-00004 · Cited by 43
Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Manabe, S., Sassa, S., & Kappas, A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.3.1060 · Cited by 40
“SA in biological fluids can be determined by gas chromatography (4, 5) or indirectly by inhibition of 6aminolevulinic acid (ALA) dehydratase, because the compound is an extremely potent inhibitor of this enzyme in human as well as in animal tissues (6, 7).”
BackgroundMethodSelf-citationMatteis, F. D., & Marks, G. S. (1983) · FEBS Letters · doi:10.1016/0014-5793(83)80430-x · Cited by 39
Iwasa, F., Sassa, S., & Kappas, A. (1989) · Biochemical Journal · doi:10.1042/bj2620807 · Cited by 39
Self-citationNeurological and Neuropsychological Problems in Tyrosinemia Type I Patients
van Ginkel, W. G., Jahja, R., Huijbregts, S. C. J., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_10 · Cited by 36
Hepatocellular carcinoma despite long‐term survival in chronic tyrosinaemia I
Kim, S. Z., Kupke, K. G., Ierardi-Curto, L. A., Holme, E., Greter, J., Tanguay, R. M., Poudrier, J., D’Astous, M., Lettre, F., Hahn, S. H., et al. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026756501669 · Cited by 40
“Succinylacetone was examined in urine indirectly by the ALA dehydratase inhibition method of Sassa and Kappas (1983) and directly by gas chromatography (Tuchman et al 1984).”
MethodMeguro, K., Igarashi, K., Yamamoto, M. P., Fujita, H., & Sassa, S. (1995) · Blood · doi:10.1182/blood.v86.3.940.bloodjournal863940 · Cited by 34
Self-citationHereditary tyrosinemia type 1 in T urkey: Twenty year single‐center experience
Zeybek, A. Ç. A., Kıykım, E., Soyuçen, E., Cansever, M. Ş., Altay, S., Zübarioğlu, T., Erkan, T., & Aydın, A. (2014) · Pediatrics International · doi:10.1111/ped.12503 · Cited by 43
Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency
Yang, H., Al‐Hertani, W., Cyr, D., Laframboise, R., Parizeault, G., Wang, S. P., Rossignol, F., Berthier, M., Giguère, Y., Waters, P. J., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104289 · Cited by 34
Sinclair, P. R., Schuetz, E. G., Bement, W. J., Haugen, S. A., Sinclair, J. F., May, B. K., Li, D., & Guzelian, P. S. (1990) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(90)90133-j · Cited by 32
Porphyric neuropathy and hereditary δ-aminolevulinic acid dehydratase deficiency in an adult
Mercelis, R., Hassoun, A., Verstraeten, L., Bock, R. D., & Martin, J. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90115-4 · Cited by 31
Ades, I. Z., Stevens, T. M., & Drew, P. D. (1987) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(87)90182-2 · Cited by 31
Biochemical Diagnosis of an Hereditary Aminolaevulinate Dehydratase Deflciency in a 63-Year-Old Man
Hassoun, A., Verstraeten, L., Mercelis, R., & Martin, J. (1989) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1989.27.10.781 · Cited by 38
Fujita, H., & Sassa, S. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb00297.x · Cited by 30
Self-citationEmanuelli, T., Prauchner, C. A., Dacanal, J., Zeni, A., Reis, E. C., Mello, C. F., & Souza, D. O. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02327-1 · Cited by 29
Fujita, H., Koizumi, A., Yamamoto, M. P., Kumai, M., Sadamoto, T., & Ikeda, M. (1984) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(84)90087-4 · Cited by 30
The common origins of the pigments of life?early steps of chlorophyll biosynthesis
Avissar, Y. J., & Moberg, P. A. (1995) · Photosynthesis Research · doi:10.1007/bf00048596 · Cited by 34
Conceptual advances in the pathogenesis and treatment of childhood metabolic liver disease
Teckman, J. H., & Perlmutter, D. H. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90229-5 · Cited by 26
Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice
Hillgartner, M. A., Coker, S. B., Koenig, A. E., Moore, M. E., Barnby, E., & MacGregor, G. G. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9949-6 · Cited by 29
Akagi, R., Yasui, Y., Harper, P., & Sassa, S. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01647.x · Cited by 24
“…is obvious, since these subjects may be more vulnerable to toxic effects of compounds which may inhibit enzyme activity, such as lead (Sassa et al, 1975), succinylacetone (Lindblad et al, 1977; Sassa & Kappas, 1983), styrene oxide (Fujita et al, 1986) or trichloroethylene (Fujita et al, 1984).”
BackgroundSelf-citationHemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2
Nagai, T., Kikuchi, S., Ohmine, K., Miyoshi, T., Nakamura, M., Kondo, T., Furuyama, K., Komatsu, N., & Ozawa, K. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21659 · Cited by 22
“We next examined IC50 values of imatinib in imatinib-resistant KCL22/SR and KU812/SR cells, incubated either in the presence or absence of succinylacetone, which is a potent inhibitor of ALA dehydratase, thereby also of heme synthesis [Sassa and Kappas, 1983].”
MethodLantum, H. B. M., Cornejo, J., Pierce, R. H., & Anders, M. W. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg104 · Cited by 25
“All three compounds were competitive inhibitors of -ALAD (Fig. 2); SA was the most potent inhibitor with a Kic of 0.15 0.05 M, followed by FA (Kic 4 1 M) and MA (Kic 20 3 M). These data indicated that the -ALAD inhibition assay was not specific for MA, FA, or SA ( Sassa and Kappas, 1983 ).”
BackgroundInfluentialTuchman, M., Freese, D. K., Sharp, H. L., Whitley, C. B., Ramnaraine, M. L., Ulstrom, R. A., Najarian, J. S., Ascher, N., Buist, N. R. M., & Terry, A. B. (1985) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01805479 · Cited by 22
Fukuda, Y., Fujita, H., Taketani, S., & Sassa, S. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb04674.x · Cited by 17
Self-citationdelta-Aminolevulinate dehydratase in human erythroleukemia cells: an immunologically distinct enzyme
Chang, C., & Sassa, S. (1985) · Blood · doi:10.1182/blood.v65.4.939.939 · Cited by 22
Self-citationMechanisms of Neuronal Damage in Acute Hepatic Porphyrias
Ricci, A., Pierro, E. D., Marcacci, M., & Ventura, P. (2021) · Diagnostics · doi:10.3390/diagnostics11122205 · Cited by 23
“SA is a by-product of tyrosine breakdown, which inhibits δ-aminolevulinic acid dehydratase (ALAD), the second enzyme of the heme biosynthetic pathway [21], thus leading to the accumulation of ALA.”
BackgroundLahiji, A. P., Anderson, K. E., Chan, A., Simon, A. R., Desnick, R. J., & Ramanujam, V. M. S. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.10.011 · Cited by 22
Elenbaas, J. S., Maitra, D., Liu, Y., Lentz, S. I., Nelson, B., Hoenerhoff, M. J., Shavit, J. A., & Omary, M. B. (2016) · The FASEB Journal · doi:10.1096/fj.201500111r · Cited by 21
Haeme-regulated Degradation of -Aminolevulinate Synthase 1 in Rat Liver Mitochondria
Yoshino, K., Munakata, H., Kuge, O., Ito, A., & Ogishima, T. (2007) · The Journal of Biochemistry · doi:10.1093/jb/mvm159 · Cited by 20
Hereditary tyrosinaemia type I: from basics to progress in treatment
Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2000) · Annals of Medicine · doi:10.3109/07853890008998832 · Cited by 21
Zhi, T., Zhou, Z., Qiu, B., Zhu, Q., Xiong, X., & Ren, C. (2019) · The Plant Journal · doi:10.1111/tpj.14235 · Cited by 18
“In animals, SUAC is an irreversible inhibitor of ALAD, the second enzyme in the heme biosynthetic pathway, which converts ALA to PBG (Sassa and Kappas, 1983; Bourque et al., 2010).”
BackgroundInfluentialSassa, S. (2002) · Photodermatology Photoimmunology & Photomedicine · doi:10.1034/j.1600-0781.2002.180202.x · Cited by 19
“The most potent inhibitor of the enzyme is succinylacetone (16), a structural analogue of ALA, which is found in urine and blood of patients with hereditary tyrosinemia, who frequently develop symptoms similar to ADP (17).”
BackgroundSelf-citationChang, C., & Sassa, S. (1984) · Blood · doi:10.1182/blood.v64.1.64.64 · Cited by 19
Self-citationPractical recommendations for biochemical and genetic diagnosis of the porphyrias
Aarsand, A. K., To‐Figueras, J., Whatley, S. D., Sandberg, S., & Schmitt, C. (2024) · Liver International · doi:10.1111/liv.16012 · Cited by 24
Mak, C. M., Lam, C.-W., Chim, S., Siu, T.-S., Ng, K.-F., & Tam, S. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.09.010 · Cited by 16
Liver in disorders of porphyrin metabolism
Rank, J. M., Straka, J. G., & Bloomer, J. R. (1990) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1990.tb01443.x · Cited by 15
Chang, C.-C., Sassa, S., & Doyle, D. J. (1984) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(84)90249-6 · Cited by 14
Self-citationSevere neurological crisis in adult patients with Tyrosinemia type 1
Dawson, C., Ramachandran, R., Safdar, S., Murphy, E., Swayne, O. B. C., Katz, J., Newsome, P. N., & Geberhiwot, T. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51160 · Cited by 14
Saraiva, R. D. A., Bueno, D., Nogara, P. A., & da Rocha, J. B. T. (2012) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2012.697810 · Cited by 16
A critical role for heme synthesis and succinate in the regulation of pluripotent states transitions
Detraux, D., Caruso, M., Feller, L., Fransolet, M., Meurant, S., Mathieu, J., Arnould, T., & Renard, P. (2023) · eLife · doi:10.7554/elife.78546 · Cited by 15
Enzyme Assays and the Porphyrias: Which Tissues and When Indicated
Hindmarsh, J. T. (1998) · Clinics in Dermatology · doi:10.1016/s0738-081x(97)00204-6 · Cited by 15
Fitzsimons, E. J., May, A. M., Elder, G. H., & Jacobs, A. (1986) · Analytical Biochemistry · doi:10.1016/0003-2697(86)90053-9 · Cited by 14
Decreased erythrocyte δ-aminolevulinate dehydratase activity after styrene exposure
Fujita, H., Koizumi, A., Teiji, F., & Ikeda, M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90723-4 · Cited by 12
DeArmond, P. D., Dietzen, D. J., & Pyle‐Eilola, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802896-4.00003-1 · Cited by 14
Effects of succinylacetone on amino acid uptake in the rat kidney
Spencer, P. D., & Roth, K. S. (1987) · Biochemical Medicine and Metabolic Biology · doi:10.1016/0885-4505(87)90015-6 · Cited by 13
Beale, S. I. (2007) · EcoSal Plus · doi:10.1128/ecosalplus.3.6.3.11 · Cited by 15
“PBGS is competitively inhibited by the ALA analogs levulinic acid (99) and 4,6-dioxoheptanoic acid (suc-cinylacetone) (100, 101).”
BackgroundVisualizing mitochondrial heme flow through GAPDH in living cells and its regulation by NO
Biswas, P., Palazzo, J., Schlanger, S. E., Jayaram, D. T., Islam, S., Page, R. C., & Stuehr, D. J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103120 · Cited by 12
The outcome of seven patients with hereditary tyrosinemia type 1
Gökay, S., Üstkoyuncu, P. S., Kardaş, F., & Kendırcı, M. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0471 · Cited by 12
“The chronic form of the disease is characterized by chronic liver disease, renal tubular dysfunction, hypophosphatemic rickets, porphyria-like neurological crisis [1, 4, 5].”
BackgroundHereditary Tyrosinemia Type 1 in Turkey
Zeybek, A. Ç. A., Kıykım, E., & Cansever, M. Ş. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_15 · Cited by 13
Differential Mechanism of ATP Production Occurs in Response to Succinylacetone in Colon Cancer Cells
Lee, P. J., Woo, S. J., Yoo, H. M., Cho, N., & Kim, H.-P. (2019) · Molecules · doi:10.3390/molecules24193575 · Cited by 12
“SA acts as an inhibitor of the enzyme 6-aminolevulinic acid dehydratase and induces dysfunctional mitochondria through the inhibition of heme synthesis [1,2].”
BackgroundBadawy, A. A. ‐. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109314 · Cited by 10
“Succinylacetone is also a potent inhibitor of the enzyme, as shown in patients with tyrosinemia [13], in whom this compound accumulates.”
BackgroundEffects of succinylacetone on growth and respiration of L1210 leukemia cells
Weinbach, E. C., & Ebert, P. S. (1985) · Cancer Letters · doi:10.1016/0304-3835(85)90048-5 · Cited by 10
Vaisman, B. L., Fibach, E., & Konijn, A. M. (1997) · Blood · doi:10.1182/blood.v90.2.831.831_831_838 · Cited by 10
Laftah, A. H., Simpson, R. J., Peters, T. J., & Raja, K. B. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.01.027 · Cited by 9
“The pathophysiology occurs in both the acute and chronic forms of the disorder (Kvittingen, 1991), with certain patients having an accompanying clinical syndrome resembling that in acute intermittent porphyria (Kang and Gerald, 1970; Sassa and Kappas, 1983) or variagate porphyria (Tschudy and Bonkowsky, 1972).”
BackgroundLaberge, C. M., Lescault, A., Grenier, A., Morissette, J., Gagné, R., Gadbois, P., & Halket, J. M. (1990) · Europe PMC (PubMed Central) · Cited by 7
Wyss, P. A., Carter, B. E., & Roth, K. S. (1992) · Biochemical Medicine and Metabolic Biology · doi:10.1016/0885-4505(92)90053-2 · Cited by 8
Approaches to Treatment and Prevention of Human Porphyrias
Anderson, K. E. (2003) · Elsevier eBooks · doi:10.1016/b978-0-08-092388-8.50016-9 · Cited by 13
An acquired acute hepatic porphyria: A novel type of δ-aminolevulinate dehydratase inhibition
Akagi, R., Prchal, J. T., Eberhart, C. E., & Sassa, S. (1992) · Clinica Chimica Acta · doi:10.1016/0009-8981(92)90140-l · Cited by 7
Self-citationThe mitochondrial carrier SFXN1 is critical for Complex III integrity and cellular metabolismPreprint
Acoba, M. G., Alpergin, E. S. S., Renuse, S., Fernández-del-Río, L., Lu, Y., Clarke, C. F., Pandey, A., Wolfgang, M. J., & Claypool, S. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.157495 · Cited by 7
Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment
Tang, Y. Y., & Kong, Y. (2021) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2021-0255 · Cited by 11
Gene-Environmental Interactions: Lessons from Porphyria
Sassa, S. (2003) · Environmental Health and Preventive Medicine · doi:10.1007/bf02908884 · Cited by 6
Self-citationSassa, S., Iwasa, F., & Galbraith, R. A. (1989) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0623-8_12 · Cited by 6
Self-citationAlkaptonuria: Leading to the Treasure in Exceptions
Cox, T. M. (2011) · JIMD Reports · doi:10.1007/8904_2011_93 · Cited by 5
“Fanconi syndrome with renal tubular acidosis may develop; and with the accumulation of the secondary metabolite, succinylacetone (4,6: dioxoheptanoate, a potent inhibitor of 5-aminolaevulinate dehydratase), neurovisceral episodes mimicking acute porphyria occur (Mitchell et al. 1990, 2001/2; Sassa and Kappas 1983).”
Background
Metadata
- Authors
- Sassa, S., & Kappas, A.
- Affiliations
- Rockefeller University Hospital (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1983-03-01
- Volume
- 71
- Issue
- 3
- Pages
- 625-634
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC436912
- OpenAlex
- W2081959583
- Semantic Scholar
- 4ac7d88a5c653026d8460d83904e6a95c71936e1
- Cited by
- 145
- References
- 39
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 4 · 2017: 5 · 2016: 8 · 2015: 3 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- hereditary tyrosinemia, succinylacetone, delta-aminolevulinic acid dehydratase, heme biosynthesis, fumarylacetoacetate hydrolase deficiency, acute intermittent porphyria, competitive inhibition, cytochrome P450, hepatocytes, erythrocytes, pharmacogenetics, urinary metabolites
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Porphobilinogen Synthase, Animals, Cattle, Chick Embryo, Erythrocytes, Heme, Heptanoates, Heptanoic Acids, Humans, Liver, Mice, Inbred BALB C, Species Specificity, Tyrosine, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.